Close

25 abril, 2021

Tocilizumab in Covid-19 Pneumonia

Severe Covid-19 pneumonia occurs in approximately 15% of patients and is associated with high mortality. Case reports and observational studies have suggested that treatment with tocilizumab causes rapid fever reduction and reduces need for oxygen support. New research findings are summarized in a short video.

Treating Severe Covid-19

Severe Covid-19 pneumonia occurs in approximately 15% of patients and is associated with high mortality. Case reports and observational studies have suggested that treatment with tocilizumab causes rapid fever reduction and reduces need for oxygen support. New research findings are summarized in a short video. https://nej.md/3atXM70

Publicado por The New England Journal of Medicine en Miércoles, 21 de abril de 2021

https://www.nejm.org/do/10.1056/NEJMdo005991/full/


Créditos: Comité científico Covid

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *